ALLIANCE PHARMACEUTICALS SAS : revenue, balance sheet and financial ratios

ALLIANCE PHARMACEUTICALS SAS is a French company founded 13 years ago, specialized in the sector Autres activités de soutien aux entreprises n.c.a.. Based in PARIS (75016), this company of category PME shows in 2024 a revenue of 10 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - ALLIANCE PHARMACEUTICALS SAS (SIREN 791824519)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue 10 109 € N/C 270 026 € 561 422 € 449 220 € 546 458 € 420 589 € 285 709 € 387 256 € 364 777 €
Net income 20 232 € 0 € -103 884 € 1 451 426 € -430 621 € 4 427 237 € -380 443 € -782 934 € -272 632 € -196 717 €
EBITDA 20 218 € -5 € 17 995 € -489 823 € 36 734 € 63 867 € -91 700 € -41 013 € -33 202 € 17 878 €
Net margin 200.1% N/C -38.5% 258.5% -95.9% 810.2% -90.5% -274.0% -70.4% -53.9%

Revenue and income statement

In 2024, ALLIANCE PHARMACEUTICALS SAS achieves revenue of 10 k€. Revenue is declining over the period 2015-2024 (CAGR: -32.9%). After deducting consumption (0 €), gross margin stands at 10 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 20 k€, representing 200.0% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 20 k€, i.e. 200.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

10 109 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

10 109 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

20 218 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

20 220 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

20 232 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

200.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 100%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 200.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.001%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

99.966%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

200.138%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.014

Solvency indicators evolution
ALLIANCE PHARMACEUTICALS SAS

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Med: 5.61
Q3: 47.03
Excellent

In 2024, the debt ratio of ALLIANCE PHARMACEUTICALS SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
99.97% 2024
2022
2023
2024
Q1: 6.21%
Med: 32.46%
Q3: 67.88%
Excellent

In 2024, the financial autonomy of ALLIANCE PHARMACEUTICALS SAS (100.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.01 years 2024
2022
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 1.29 years
Average +25 pts over 2 years

In 2024, the repayment capacity of ALLIANCE PHARMACEUTICALS SAS (0.01) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 4080.24. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

4080.244

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
ALLIANCE PHARMACEUTICALS SAS

Sector positioning

Liquidity ratio
4080.24 2024
2022
2023
2024
Q1: 120.11
Med: 218.14
Q3: 571.7
Excellent +11 pts over 3 years

In 2024, the liquidity ratio of ALLIANCE PHARMACEUTICALS SAS (4080.24) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.0x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 1.61x
Average -50 pts over 3 years

In 2024, the interest coverage of ALLIANCE PHARMACEUTICALS SAS (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 360 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: -189 days. The gap of 549 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 19362 days of revenue, i.e. 544 k€ to permanently finance. Over 2015-2024, WCR increased by +163%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

543 688 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

360 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

-189 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

19362 j

WCR and payment terms evolution
ALLIANCE PHARMACEUTICALS SAS

Positioning of ALLIANCE PHARMACEUTICALS SAS in its sector

Comparison with sector Autres activités de soutien aux entreprises n.c.a.

Valuation estimate

Based on 131 transactions of similar company sales (all years), the value of ALLIANCE PHARMACEUTICALS SAS is estimated at 63 522 € (range 19 274€ - 125 881€). With an EBITDA of 20 218€, the sector multiple of 4.8x is applied. The price/revenue ratio is 0.36x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
131 transactions
19k€ 63k€ 125k€
63 522 € Range: 19 274€ - 125 881€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
20 218 € × 4.8x
Estimation 98 053 €
29 443€ - 168 682€
Revenue Multiple 30%
10 109 € × 0.36x
Estimation 3 605 €
1 801€ - 6 814€
Net Income Multiple 20%
20 232 € × 3.3x
Estimation 67 073 €
20 066€ - 197 482€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 131 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Autres activités de soutien aux entreprises n.c.a.)

Compare ALLIANCE PHARMACEUTICALS SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Autres activités de soutien aux entreprises n.c.a.

Frequently asked questions about ALLIANCE PHARMACEUTICALS SAS

What is the revenue of ALLIANCE PHARMACEUTICALS SAS ?

The revenue of ALLIANCE PHARMACEUTICALS SAS in 2024 is 10 k€.

Is ALLIANCE PHARMACEUTICALS SAS profitable?

Yes, ALLIANCE PHARMACEUTICALS SAS generated a net profit of 20 k€ in 2024.

Where is the headquarters of ALLIANCE PHARMACEUTICALS SAS ?

The headquarters of ALLIANCE PHARMACEUTICALS SAS is located in PARIS (75016), in the department Paris.

Where to find the tax return of ALLIANCE PHARMACEUTICALS SAS ?

The tax return of ALLIANCE PHARMACEUTICALS SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does ALLIANCE PHARMACEUTICALS SAS operate?

ALLIANCE PHARMACEUTICALS SAS operates in the sector Autres activités de soutien aux entreprises n.c.a. (NAF code 82.99Z). See the 'Sector positioning' section above to compare the company with its competitors.